Advanced Therapy Medicinal Products (ATMPs) have the potential to revolutionize medicine by offering personalized and targeted treatments, such as gene therapy, cell therapy, and tissue-engineered products. They promise to cure or significantly improve outcomes for previously untreatable conditions, reduce long-term healthcare costs, and enhance patients' quality of life by addressing the root causes of diseases at the cellular and genetic levels. Many of these advanced medicinal products cannot be cryopreserved like many other biological drugs but instead require tightly controlled environmental conditions to be kept functional. These constraints complicate and often prohibit transport of materials during manufacturing and also final product to the patients. In this project, we will develop a solution for global transport of ATMPs to fully unleash the potential of live cell-based products for the cell therapy and regenerative medicine markets, where access to increasingly complex and sensitive clinical-grade biological materials will be critical for treating patients throughout the EU and globally.
The Cellbox Go/AT will establish a new value chain and is a market-creating innovation. Advanced therapy medicinal product (ATMP) manufacturers face the challenge of producing highly specialized cells and tissues, but currently cannot ship them under adequate conditions because the appropriate transport vessels do not exist. For the first time, Cellbox Go/AT will enable the transport of biomaterials which cannot be frozen or should not be frozen due to their fragile nature. At present, no marketable solution exists for this need. Accordingly, there is an opportunity to disrupt the existing value chain and market for the established transports of ATMPs.
